GlassScriptPhysician profile
Anna Cobb Turner
NPI 1952867210
$4,264.24
in general payments reported to CMS, 2019-2025
29 companies · $1,376 in 2025
The $1,376 reported for 2025 was more than what 91% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $468 · 2022: $190 · 2023: $978 · 2024: $1,252 · 2025: $1,376.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,606.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,606.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $608.50 | 2023-2025 | Proclaim, Ionicrf |
| Abbvie INC. | $568.22 | 2022-2025 | |
| Collegium Pharmaceutical, INC. | $543.72 | 2021-2025 | Xtampza |
| Scilex Pharmaceuticals INC. | $463.25 | 2021-2025 | Ztlido |
| Indivior INC. | $240.14 | 2023-2025 | Sublocade |
| Medtronic, INC. | $205.23 | 2024-2025 | Intellis Adaptivestim, Synchromedii |
| Mml US, INC. | $163.86 | 2023-2025 | Reactiv8 |
| Pfizer INC. | $155.54 | 2023-2025 | |
| Axsome Therapeutics, INC. | $144.85 | 2025 | Symbravo |
| Nevro Corp. | $135.94 | 2021 | |
| Averitas Pharma INC. | $124.70 | 2023-2024 | Qutenza |
| Globus Medical, INC. | $121.40 | 2025 | Senza |
| Melinta Therapeutics, LLC | $104.71 | 2022 | |
| Almatica Pharma LLC | $82.10 | 2021-2023 | Gralise |
| Uswm, LLC | $81.96 | 2023 | Zimhi, Lucemyra |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $78.84 | 2021-2023 | Emgality |
| Amgen INC. | $71.90 | 2021 | |
| Vertex Pharmaceuticals Incorporated | $64.00 | 2024-2025 | |
| Ibsa Pharma INC. | $52.74 | 2023-2024 | Tirosint, Licart, Tirosint |
| Lundbeck LLC | $50.15 | 2023 | Vyepti |
| Spinal Simplicity, LLC | $43.07 | 2023-2025 | Ha Minuteman G3-R |
| Redhill Biopharma INC. | $31.53 | 2021 | |
| Bioventus LLC | $30.92 | 2023 | Stimrouter Implantable Kit |
| Spr Therapeutics, INC | $20.13 | 2023 | Sprint Pns System |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $19.19 | 2025 | Relistor |
| Biodelivery Sciences International, INC. | $17.89 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $15.06 | 2023 | Seglentis |
| Arbor Pharmaceuticals, INC. | $13.33 | 2022 | |
| Boston Scientific Corporation | $11.37 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anna Turner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.